Venus Remedies expands reach with the launch of Elores in Ecuador
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Dozee Pro Ex will offer Ambulatory patient monitoring for a seamless continuum of patient monitoring across different care settings
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Increased capability to produce medicines for challenging diseases including cancer
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Subscribe To Our Newsletter & Stay Updated